

Structural Biology and Drug Discovery

Colby Sandate

EPFL

08-05-2025

What is structural biology?

- Scientific field that produces information on the 3D structure of biological macromolecules (proteins, nucleic acids and their assemblies) using a variety of techniques such as:
 - X-ray crystallography
 - Nuclear magnetic resonance spectroscopy (NMR)
 - Cryo-electron microscopy (cryo-EM)
 - Small angle X-ray scattering (SAXS)
 - And others


The role of structural biology in biopharma

- 3D characterization of macromolecules provides critical insights into their function, dynamics, and interactions with potentially therapeutic compounds.
 - Provides targets for therapeutics development.
- Characterization of protein-ligand interactions (and often drug mechanism of action).
 - Resolving details of binding sites can lead to the development of compounds with improved selectivity and potency, minimizing off-target effects and improving efficacy.


The role of structural biology in biopharma

- Characterization of protein-ligand interactions (and often drug mechanism of action).
 - Resolving details of binding sites can lead to the development of compounds with improved selectivity and potency, minimizing off-target effects and improving efficacy.

Structural data provides critical information for biological processes – and opportunities for therapeutics




Qin Q, et al. (2022) *Int. J. Mol. Sci.*



We D, et al. (2015) *Nature*

Ligand binding pockets in proteins




-Majority of drugs bind to cavities within proteins. Besides differing in shape & size, these cavities are generated by chiral residues which bring differing properties to the cavity's surface (charge, hydrophobicity, H-bond donors and acceptors).

-Identification of ligand binding pockets in proteins allows for structure-based drug design (SBDD).

-No consensus exists for definition or gold standard for binding pocket.


-Average volume of drug-binding cavity is $\sim 930\text{Å}^3$.

A golden age for structural biology




Source: www.rcsb.org

Growth of small molecules coordinates in the PDB




X-ray Crystallography




<https://www.britannica.com/science/X-ray-diffraction>

Simplified workflow




<https://www.creative-biostructure.com/protein-crystallography-452.htm>

Why are crystals necessary?




Protein crystallization



- Key bottleneck for X-ray crystallography.
- May require extensive condition optimization (buffers and additives, construct boundaries and protein engineering).
- Flexibility, size, asymmetry and disorder may be refractory to crystallization.
- However optimized conditions allow for high throughput efforts.

Wlodawer A, Dauter Z, Jaskolski M, (2017)
Springer Protocols: Protein Crystallography.


Crystal soaking with small molecules



- Protein crystals contain many solvent-filled channels (~50% total volume).
- Small molecules diffuse through crystals and interact with proteins as if they were in solution.
- Can allow for high throughput work of determining protein-ligand complexes.

Wlodawer A, Dauter Z, Jaskolski M, (2017)
Springer Protocols: Protein Crystallography.


Case Study: Imatinib (Glivec)




<https://rexmedical.co.nz/products/other/imatinib>

<https://de.wikipedia.org/wiki/Imatinib>


Receptor Tyrosine Kinases (RTK) overview




Mechanisms of RTK hyperactivation



The BCR-ABL fusion protein is a result of chromosomal translocation, often in hematopoietic stem cells






- Constitutively active kinase (does not need ligand or dimerization for activity).
- Globular and cytosolic (does not respond to receptor-based inhibitors).
- Upregulated intracellular signaling through phosphorylating substrates.



Sattlermc M, Griffin JD (2003) *Seminars in Hematology*

Imatinib binds the ATP binding pocket of ABL



Young MA, et al. (2006) *Cancer Res*

PDB: 2G1T

Large compound screens and structure-activity studies resulted in Imatinib





Table 1
Inhibitory profile against a panel of protein kinases

Kinase	Inhibitory concentration (IC_{50} nM)			
	A	B	C	Glivec
cAbl	3300 ± 1100	2800 ± 850	361 ± 48	188 ± 18
Kit	1100 ± 200	1100 ± 180	785 ± 140	413 ± 23
PDGFR- β	390 ± 58	870 ± 110	400 ± 72	386 ± 111
VEGFR-2 (Human KDR)	1400 ± 210	1300 ± 310	10,000	10,000
EGFR (HER-1; Erb B)	$>10,000$	$>10,000$	$>10,000$	$>10,000$
FGFR-1	2500	$>10,000$	$>10,000$	$>10,000$
CMet	n.d.	$>10,000$	$>10,000$	$>10,000$
IGF-R	$>10,000$	$>10,000$	$>10,000$	$>10,000$
CDK1/cyclinB	92 ± 4	200 ± 37	$>10,000$	$>10,000$
CSrc	1700 ± 100	$>10,000$	$>10,000$	$>10,000$
PKC- α	1000	1200	72,000	$>10,000$

Data represent the mean \pm SEM ($n \geq 3$) drug concentrations required to inhibit enzyme activity by 50% (IC_{50} value; nM) at ATP concentrations optimized for each kinase. Alternative nomenclature for the kinases is given in parenthesis. n.d. = not determined.

Manley PW *et al.* (2002) *European Journal of Cancer*


Case Study: Captopril - from snake venom to the clinic



<https://www.denkpharma.com/products/pharmaceuticals/captopril>

<https://en.wikipedia.org/wiki/Captopril>

The RAAS creates a proteolytic cascade that results in constriction of the vasculature



Peptides found within the venom of *Bothrops jararaca* inhibit the renin-angiotensin aldosterone system






Fig. 4. The effect of bradykinin potentiating factor (BPF) upon the arterial hypotension produced in a cat by bradykinin. (a) Before; (b), (c) and (d) 3, 15 and 30 min after 2 mg/kg of BPF. B_1 , 1 μ g/kg and B_2 , 2 μ g/kg of synthetic bradykinin. Drugs were injected intravenously. Time marks, 1 min.

https://en.wikipedia.org/wiki/Bothrops_jararaca

Ferreira SH (1965) *Brit. J. Pharmacol*

Teprotide, a synthetic ACE inhibitor



<https://en.wikipedia.org/wiki/Teprotide#/media/File:Teprotide.svg>


Gavras H, et al. (1974) *N. Engl. J. Med.*

The search for an orally available small molecule ACE inhibitor


- Teprotide has a short half-life due to proteolytic activity in animals.
- Commercial interest in peptide ACE inhibitors waned.
- Lead compound screens ended in failure.

Failure to find an small molecule ACE inhibitor lead to studies on carboxypeptidase A

ACE active site



Carboxypeptidase A active site



Jensen AF, et al. (2002) *J Biol Inorg Chem*

Acharya KR, et al. (2003) *Nature Reviews Drug Discovery*

L-Benzylsuccinate is an inhibitor of Carboxypeptidase A




Figure 1. Scheme comparing (a) the benzylsuccinate molecule with (b) the products of peptide hydrolysis.



Mangani S, et al. (1991) *J. Mol. Biol.*

Captopril was inspired by L-benzylsuccinate and synthesized shortly after

Structure	Designation	Angiotensin-converting enzyme of rabbit lung (IC ₅₀)	Activity (μg/ml)			
			Excised guinea pig ileum			
			AI (IC ₅₀)	AII (IC ₅₀)	Ach IC ₅₀	BK (AC ₅₀)
1 <Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro	(SQ20,881)	1.0	0.068	> 32	> 32	0.0017
2 HO ₂ C-CH ₂ -CH ₂ -CO-N ⁺ CH ₂ CH ₂ CO ₂ H		135	94	>100	>100	8.0
3 HO ₂ C-CH ₂ -CH ₂ -CH ^{CH₃} -CO-N ⁺ CH ₂ CH ₂ CO ₂ H	(SQ13,297)	12	13	>100	>100	0.2
4 HO ₂ C-CH ₂ -CH ₂ -CH ^{CH₃} -CO-N ⁺ CH ₂ CH ₂ CO ₂ H		340	>100	>100	>100	15
5 HO ₂ C-CH ₂ -CH ₂ -CH ^{CH₃} -CO-N ⁺ CH ₂ CH ₂ CO ₂ H		1.0	4.6	>100	>100	1.0
6 HO ₂ C-CH ₂ -CH ₂ -CH ^{CH₃} -CO-N ⁺ CH ₂ CH ₂ CO ₂ H		230	>100	>100	>100	4.7
7 HS-CH ₂ -CH ₂ -CO-N ⁺ CH ₂ CH ₂ CO ₂ H	(SQ13,863)	0.04	0.06	>100	>100	0.005
8 HS-CH ₂ -CH ₂ -CH ^{CH₃} -CO-N ⁺ CH ₂ CH ₂ CO ₂ H	(SQ14,225)	0.005	0.005	>100	>100	0.0007
9 HS-CH ₂ -CH ₂ -CH ^{CH₃} -CO-N ⁺ CH ₂ CH ₂ CO ₂ H		0.50	1.7	>100	>100	3.1

Ondetti MA, et al. (1977) *Science*

Toxicity associated with high doses of Captopril leads to the development of Enalapril and others




<https://en.wikipedia.org/wiki/Enalapril>

Gavras H, et al. (1981) *The Lancet*

Cryo-EM Introduction





https://cfim.ku.dk/equipment/electron_microscopy/titankrios/






Inkson BJ, (2016) Materials Characterization Using Nondestructive Evaluation (NDE) Methods


Resolution Revolution






Electron microscopy grid








3 μ L sample



100,000 times too thick








- non radio




























Antibody discovery using cryo-EM




-Rhesus macaque were immunized with soluble HIV Env trimers.

-Trimers were purified by immunoaffinity chromatography and then subjected to single particle analysis.

-Fab-corresponding parts of bound antibodies were sequenced in a combined approach using the cryo-EM density and b cell receptor time of immunization sequencing databases.


-Hybrid structural and bioinformatics approach that identifies mAbs that bind to specific epitopes.

Cryo-EM and SARS-CoV-2





Rapid studies of the spike protein trimer revealed an active conformation, “RBD up”, which is ACE2 receptor accessible.


Previous structural data of MERS-CoV discovered two mutations in the spike protein that prevent a post-fusion conformation



The double proline mutation also stabilize the receptor-binding conformation of the SARS-CoV-2 Spike




$$K_D = 14.7 \text{ nM}$$
$$k_a = 1.88 \times 10^5 \text{ M}^{-1}\text{s}^{-1}$$
$$k_d = 2.76 \times 10^{-3} \text{ s}^{-1}$$




Wrapp D et al. (2020) *Science*

Construct was designed for cryo-EM experiments, but is also very well suitable for serological assays




Wrapp D et al. (2020) *Science*

Identification of neutralizing antibodies derived from convalescent COVID-19 patients




Neutralization occurs by sterically blocking ACE2 interaction or preventing binding-competent conformations.

Cryo-electron tomography





In situ workflow



Single particle-like workflow resulting in high resolution reconstruction

Antibiotic-bound ribosomes



Xue L, et al. (2022) *Nature*

Tegunov D, et al. (2021) *Nature Methods*

Cryo-ET Pros and Cons


- Pro
- Most native conditions compared to any structural technique.
- Full complexity of the cellular environment maintained (crowding, PPIs, ultrastructure..).
- Best when studying large and highly populated assemblies.

Cryo-ET Pros and Cons

- Cons
- Very low throughput, especially for *in situ* cryo-ET.
- Single particle workflow is currently limited to a few large and distinguishable complexes (ribosome, proteasome, nuclear pore complex...)




Machine learning in drug discovery

- Traditional approaches to drug discovery has a steep failure rate and incur significant costs.
- Advances in AI-based techniques may accelerate drug discovery while reducing both failure rate and associated costs.





Catacutan DB, et al. (2024) *Nature Chemical Biology*

Identification of antibiotic abaucin through deep learning-guided discovery





~7,500 molecules were screen for growth inhibition for *A. baumannii*, serving as a training dataset for ML which associated structural information with predicted antibiotic activity.

Identification of antibiotic abaucin through deep learning-guided discovery



Abaucin shows selective potency against *A. baumannii*, and can suppress infection in a wound model.

Abaucin-resistant clones displayed mutations in lipoprotein trafficking protein LolE



E. coli LolE structure compared to predicted structure of *A. baumannii* LolE

Thank you!

Any Questions?